Acute liver failure (ALF) is a rare but devastating condition that arises from diverse etiologies, has a high mortality and requires high resource utilization including transplantation.
The Acute Liver Failure Study Group (ALFSG) has been funded by NIDDK since 1997 to collect detailed clinical data on more than 3,300 patients with severe liver injury that can lead to death or need for liver transplantation. The registry closed for new enrollments in 2019. The group continues to analyze data and utilize bio-samples from the NIDDK repository as well as providing data and samples to investigators around the world. We envisioned a two day symposium to reflect on what has been accomplished and what challenges lie ahead in the area of diagnosing and managing acute liver failure and related conditions.
The Acute Liver Failure: Science and Practice two-day symposium scheduled for March 30-31, 2020 was not held because of the Covid pandemic. It is now tentatively scheduled for March 28-29, 2022, to be held on the UT Southwestern Medical Center campus, Dallas, Texas. The final speaker list is pending but the topics and most of the speakers will be identical to the planned meeting in 2020. At this point, the meeting will be in person but may also be streamed online.
March 28-29, 2022
UT Southwestern Campus
Who should attend?
Basic scientists that work on liver injury and clinicians (hepatologists, surgeons) who care for these very ill patients.
This two day program will provide a comprehensive understanding of all aspects of the pathogenesis and treatment of ALF including possible future therapies. The initial day of the meeting will be devoted to allowing investigators to present work pertaining to pathogenesis and disease mechanisms. The second day of the meeting will be devoted to reviewing aspects of disease management including evaluation, treatment and consideration of prognosis, liver transplantation and liver support devices.
This course/program is endorsed by AASLD. The Acute Liver Failure Study Group is pleased to have received the endorsement of the American Association for the Study of Liver Diseases (AASLD). Copyright © 2020 by the American Association for the Study Diseases. All rights reserved.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.